What the FDA labels say about taking them together
Paliperidone and risperidone
Paliperidone's FDA label of January 31, 2025 names risperidone in its contraindications section, and risperidone's label names paliperidone too. The risperidone label: “CONTRAINDICATIONS RYKINDO is contraindicated in patients with a known hypersensitivity to risperidone, its metabolite, paliperidone, or to any of its components.”
Check it at the source: the paliperidone FDA label on DailyMed (effective January 31, 2025, Janssen Pharmaceuticals, Inc.); the risperidone FDA label on DailyMed (effective May 28, 2026, Janssen Pharmaceuticals, Inc.).
What does the paliperidone label say about risperidone?
Paliperidone label, contraindicationsCONTRAINDICATIONS INVEGA is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the INVEGA formulation.
Paliperidone label, warnings and precautionsPaliperidone has a prolactin-elevating effect similar to that seen with risperidone, a drug that is associated with higher levels of prolactin than other antipsychotic drugs.
Source: FDA drug label (Erzofri Extended-Release, NDA216352), Shandong Luye Pharmaceutical Co., Ltd., effective March 9, 2026 (SPL set 492bf9dd-868e-421a-92db-8cca8973aac1), via openFDA
Source: FDA drug label (Invega Sustenna, NDA022264), Janssen Pharmaceuticals, Inc., effective February 14, 2025 (SPL set 1af14e42-951d-414d-8564-5d5fce138554), via openFDA
Source: FDA drug label (INVEGA), Janssen Pharmaceuticals, Inc., effective January 31, 2025 (SPL set 7b8e5b26-b9e4-4704-921b-3c3c0d159916), via openFDA; the full label on DailyMed
What does the risperidone label say about paliperidone?
Risperidone label, contraindicationsCONTRAINDICATIONS RISPERDAL is contraindicated in patients with a known hypersensitivity to either risperidone or paliperidone, or to any of the excipients in the RISPERDAL formulation.
Source: FDA drug label (Risperdal Consta, NDA021346), Janssen Pharmaceuticals, Inc., effective November 5, 2025 (SPL set bb34ee82-d2c2-43b8-ba21-2825c0954691), via openFDA
Source: FDA drug label (Rykindo Extended-Release Microspheres, NDA212849), Shandong Luye Pharmaceutical Co., Ltd., effective May 26, 2026 (SPL set 58534c96-96f5-4c2e-a061-92d4506aee91), via openFDA
Source: FDA drug label (Risperidone, NDA020588), Janssen Pharmaceuticals, Inc., effective August 20, 2026 (SPL set 701e1cd8-2868-4d29-85a9-a2212c88165f), via openFDA
Source: FDA drug label (RISPERDAL), Janssen Pharmaceuticals, Inc., effective May 28, 2026 (SPL set 7e117c7e-02fc-4343-92a1-230061dfc5e0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Paliperidone | Risperidone | |
|---|---|---|
| Labeled for | Schizophrenia | Bipolar disorder, Schizophrenia |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.972 per tablet 3 mg tablet | $0.0368 per tablet 0.25 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once